ON
← Back to feed
«Ils reportent leur envie de sucre sur le parfum» : comment Ozempic est en train de révolutionner le marché des sent-bon
France🎭 Culture21 days ago

«Ils reportent leur envie de sucre sur le parfum» : comment Ozempic est en train de révolutionner le marché des sent-bon

In the United States, where one in eight people have used GLP-1-based treatments like Ozempic primarily as appetite suppressants, the sale of gourmet perfumes is experiencing a surge and is influencing global fragrance trends.

How each side covered it

The same event, grouped by the political lean of the outlets covering it.

How each side covered it

Support independent, bias-aware news and unlock the social pulse, community voting, and your personalized For You feed.

Become a Supporter

Covered around the world

The same event as reported in other countries.

Covered around the world

Support independent, bias-aware news and unlock the social pulse, community voting, and your personalized For You feed.

Become a Supporter

Claims check

Key factual claims, and how many sources assert vs dispute each.

Claims check

Support independent, bias-aware news and unlock the social pulse, community voting, and your personalized For You feed.

Become a Supporter

1 reports

Le Figaro logoLe FigaroIndependent🔒Center21 days ago
«Ils reportent leur envie de sucre sur le parfum» : comment Ozempic est en train de révolutionner le marché des sent-bon

In the United States, where one in eight people have used GLP-1-based treatments like Ozempic primarily as appetite suppressants, the sale of gourmet perfumes is experiencing a surge and is influencing global fragrance trends.

Bias read (Center): The article discusses market trends related to Ozempic and gourmet perfumes without taking a stance on political issues. It focuses on consumer behavior and industry changes, which are not inherently politically charged.

Keep the news honest.

ObjectiveNews is reader-funded and ad-free — we show you the bias instead of hiding it. Support independent journalism for €5/month.

Become a Supporter

Related stories